{"schema_version":"1.0","type":"article","title":"胰臟癌新藥打贏化療5週賣65億，智擎一好一壞","url":"https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5.md","lang":"zh-Hant","date":"2026-11-07","publish_at":"2026-11-07T08:00:00+08:00","updated_at":"2026-11-07","category":"商業分析系列","topic":"商業分析系列","tags":["胰臟癌","Rasonque","RAS 標靶","智擎","PRMT5"],"summary":"Revolution Medicines 的胰臟癌口服新藥 Rasonque 上市約五週，美國淨營收 1.976 億美元、超過 5,000 名病人用藥，是分析師預估的七倍。二線化療最先讓位，下一戰在一線與 RAS 加 PRMT5 聯用；對台灣智擎是一好一壞。","key_points":["Rasonque 的爆量證明胰臟癌是被化療壓低的大市場，2027 年全年淨銷售會超過 20 億美元。","第三季營收含恩慈用藥轉換與首次鋪貨，但扣掉這些，仍是 Lumakras 上市頭四個月的四倍多，二線化療首當其衝。","Rasonque 對智擎（4162）一好一壞：二線 Onivyde 先被取代，一線 NALIRIFOX 在 RASolute 303 結果前仍守得住；自研 PRMT5 抑制劑 PEP08 方向對，但 2026 年 11 月仍在第一期。"],"facts":[{"claim":"FDA 核准 Rasonque（daraxonrasib）","value":"2026-08-26","unit":"date","as_of":"2026-08-26","source":"FDA 2026-08-26"},{"claim":"Rasonque 2026Q3 美國淨產品營收（約五週）","value":197.6,"unit":"百萬美元","as_of":"2026-11-04","source":"Revolution Medicines 2026-11-04"},{"claim":"核准至 9/30 美國商業用藥病人數","value":">5000","unit":"人","as_of":"2026-11-04","source":"Revolution Medicines 2026-11-04"},{"claim":"給付覆蓋美國胰臟癌保險人口比例","value":">90","unit":"%","as_of":"2026-11-04","source":"Revolution Medicines 2026-11-04"},{"claim":"批發價（每 30 天）","value":39800,"unit":"美元","as_of":"2026-08-27","source":"Stocktwits 2026-08-27"},{"claim":"RBC 估 2026Q3 美國營收","value":28,"unit":"百萬美元","as_of":"2026-08-27","source":"Stocktwits 2026-08-27"},{"claim":"RBC 估長期年銷售","value":11.5,"unit":"十億美元","as_of":"2026-08-27","source":"Stocktwits 2026-08-27"},{"claim":"RASolute 302 中位總存活 Rasonque vs 化療","value":"13.2 vs 6.7","unit":"月","as_of":"2026-08-26","source":"FDA 2026-08-26"},{"claim":"RASolute 302 總存活風險比","value":0.4,"unit":"HR","as_of":"2026-08-26","source":"FDA 2026-08-26"},{"claim":"治療相關副作用停藥率 Rasonque vs 化療（RAS G12 族群）","value":"1.2 vs 11.2","unit":"%","as_of":"2026-05-31","source":"OncoDaily 2026-05-31"},{"claim":"核准前恩慈用藥供藥病人數","value":">2000","unit":"人","as_of":"2026-08-05","source":"Revolution Medicines 2026-08-05"},{"claim":"毛額到淨額扣減區間（Q3 落在低端）","value":"20-30","unit":"%","as_of":"2026-11-04","source":"Gloom 2026-11-04"},{"claim":"Lumakras 上市至 2021Q3 累計營收","value":45,"unit":"百萬美元","as_of":"2021-11-02","source":"Amgen 2021-11-02"},{"claim":"Ipsen 不再預期 Onivyde 與 Tazverik 尖峰銷售","value":500,"unit":"百萬歐元","as_of":"2026-02-12","source":"Ipsen 2026-02-12"},{"claim":"vopimetostat＋Rasonque 在 MTAP 缺失胰臟癌客觀緩解率（22 人）","value":82,"unit":"%","as_of":"2026-10-23","source":"pharmaphorum 2026-10-23"},{"claim":"MTAP 缺失佔胰臟癌比例","value":"18-40","unit":"%","as_of":"2026-10-23","source":"pharmaphorum 2026-10-23"},{"claim":"歐盟 CHMP 建議核准日","value":"2026-10-15","unit":"date","as_of":"2026-11-04","source":"Gloom 2026-11-04"},{"claim":"Revolution 2026Q3 淨虧損","value":407.5,"unit":"百萬美元","as_of":"2026-11-04","source":"Revolution Medicines 2026-11-04"},{"claim":"智擎 2026 上半年營收","value":4.98,"unit":"億新台幣","as_of":"2026-08-06","source":"富果研究 2026-08-06"},{"claim":"智擎 2026 上半年歐亞銷售權利金","value":3.13,"unit":"億新台幣","as_of":"2026-08-06","source":"富果研究 2026-08-06"},{"claim":"Onivyde 一線組合納入台灣健保","value":"2025-12-01","unit":"date","as_of":"2026-08-06","source":"富果研究 2026-08-06"},{"claim":"新台幣兌美元收盤","value":32.821,"unit":"新台幣/美元","as_of":"2026-11-04","source":"中央社 2026-11-04"}],"sections":["01｜五週、五千人：一份讓分析師改模型的財報","02｜為什麼爆量：醫師和病人等這顆藥等太久","03｜一次性紅利有多大：別把第三季乘以四","04｜它吃掉誰：二線化療最先讓位","05｜下一個戰場：一線治療與「RAS 加 PRMT5」","06｜台灣：智擎手上有一線化療，也押了 PRMT5","台股連結","07｜會讓爆量降溫的地方","08｜2027 年的帳：20 億美元門檻","參考資料"],"references":[{"title":"Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress","source":"Revolution Medicines","date":"2026-11-04","url":"https://www.globenewswire.com/news-release/2026/11/04/3395785/0/en/revolution-medicines-reports-third-quarter-2026-financial-results-and-update-on-corporate-progress.html"},{"title":"Revolution Medicines Q3 2026 Earnings Call Transcript","source":"Gloom","date":"2026-11-04","url":"https://gloom.sh/stocks/rvmd/transcripts/q3-2026"},{"title":"FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma","source":"FDA","date":"2026-08-26","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma"},{"title":"Revolution Medicines Reports Second Quarter 2026 Financial Results","source":"Revolution Medicines（SEC 8-K","date":"2026-08-05","url":"https://www.sec.gov/Archives/edgar/data/0001628171/000119312526335039/rvmd-ex99_1.htm"},{"title":"RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill","source":"Stocktwits","date":"2026-08-27","url":"https://stocktwits.com/news-articles/markets/equity/rvmd-stock-stays-flat-despite-fda-nod-for-39-800-a-month-pancreatic-cancer-pill-is-drug-price-overshadowing-approval/cZYVdfIRJp2"},{"title":"RASolute 302 Trial: Daraxonrasib in mPDAC","source":"OncoDaily","date":"2026-05-31","url":"https://oncodaily.com/oncolibrary/rasolute-302-trial-daraxonrasib-mpdac"},{"title":"Amgen Reports Third Quarter 2021 Financial Results","source":"Amgen（SEC 8-K","date":"2021-11-02","url":"https://www.sec.gov/Archives/edgar/data/318154/000031815421000042/amgn-2021930xq3ex991.htm"},{"title":"Ipsen delivers strong results in 2025 and provides 2026 guidance","source":"Ipsen","date":"2026-02-12","url":"https://www.biospace.com/press-releases/ipsen-delivers-strong-results-in-2025-driven-by-solid-execution-across-all-therapeutic-areas-and-provides-2026-guidance"},{"title":"FDA approves Onivyde as first-line treatment for metastatic pancreatic cancer","source":"Healio","date":"2024-02-13","url":"https://www.healio.com/news/hematology-oncology/20240213/fda-approves-onivyde-as-firstline-treatment-for-metastatic-pancreatic-cancer"},{"title":"ESMO26: Tango sees 82% ORR with combo in pancreatic cancer","source":"pharmaphorum","date":"2026-10-23","url":"https://pharmaphorum.com/news/esmo26-tango-sees-82-orr-combo-pancreatic-cancer"},{"title":"Tango Therapeutics Reports Second Quarter 2026 Financial Results","source":"Tango Therapeutics（SEC 8-K","date":"2026-08-11","url":"https://www.sec.gov/Archives/edgar/data/0001819133/000119312526343434/tngx-ex99_1.htm"},{"title":"Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration","source":"Revolution Medicines","date":"2026-08-10","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical"},{"title":"智擎 2026 年上半年法說會重點","source":"富果研究","date":"2026-08-06","url":"https://blog.fugle.tw/post/earnings-call-4162-2026-08-06"},{"title":"PharmaEngine PEP08 reaches enrollment milestone using XtalPi platform","source":"VIR","date":"2026-05-04","url":"https://vir.com.vn/pharmaengine-pep08-reaches-enrollment-milestone-using-xtalpi-platform-151880.html"},{"title":"114年死因統計結果分析","source":"衛生福利部","date":"2026-06-22","url":"https://mohw.gov.tw/cp-16-86970-1.html"},{"title":"新台幣貶6.1分 收32.821元","source":"中央社","date":"2026-11-04","url":"https://www.cna.com.tw/news/afe/202611040213.aspx"},{"title":"「癌王」新藥在美獲批：死亡風險下降60%","source":"東方財富網","date":"2026-08-29","url":"https://finance.eastmoney.com/a/202608293859224396.html"}],"images":[{"alt":"圖1｜上市初期營收：預估、前輩與實績","url":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5/figure-01.png"},{"alt":"圖2｜Rasonque 怎麼抓住 RAS","url":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5/figure-02.png"},{"alt":"圖3｜胰臟癌治療地圖正在重畫","url":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5/figure-03.png"},{"alt":"圖4｜台灣在這場換代裡的位置","url":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-07）。胰臟癌新藥打贏化療5週賣65億，智擎一好一壞。https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}